Figure 3

(A) Continuous oral treatment with tobacco leaves expressing 500 μg GAD (gray, short dash), 250 μg CTB-hpINS (black, short dash), or the combination of both (gray, solid line), were compared to untreated (black, solid line) or WT control tobacco-treated animals (black, long dash), P = 0.24 (Log-rank test). (B) Animals experiencing catastrophic failure (black), non-catastrophic failure (gray), or no failure (those animals that survived to 32 weeks of age, white) are represented P = 0.08 (Chi-square test). T1D incidence did not differ between Phase 1 (dashed lines, treatment duration: 10 weeks) and Phase 2 (solid lines, treatment duration: ongoing through study endpoint) for (C) CTB-hpINS, (D) GAD, and (E) WT tobacco-treated animals P = 0.97, P = 0.96, and P = 0.32, respectively (Log-rank test). Number of animals (n) per group is indicated in the figure.